Portal de recerca
A MULTICENTRE NON-INTERVENTIONAL STUDY TO ASSESS THE REAL-WORLD EFFECTIVENESS OF OCRELIZUMAB IN PATIENTS WITH RELAPSING OR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS – THE MUSICALE STUDY.
Dades bàsiques
- Protocol:
- ROC-OCR-2019-01 (MN39889)
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2019
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
An algorithm to predict intrathecal synthesis of IgG with high efficiency
Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura
Meeting Abstract. 2023
An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.
Bracher A; (...); Dornmair K
Article. 10.1002/acn3.50974. 2020
Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; (...); Cháfer-Pericás C
Article. 10.3390/ijms24021226. 2023
Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study.
Zamora MG; (...); Pericas CC
Article. 10.1016/j.phrs.2024.107295. 2024
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; (...); Comabella M
Article. 10.1212/NXI.0000000000200270. 2024
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal, Enric; (...); Villar LM
Article. 10.1001/jamaneurol.2023.0010. 2023
Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.
Garcia-Lluch, Gemma; (...); Chafer-Pericas, Consuelo
Article. 10.1177/13872877241304995. 2024
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.
Boix Lago, A.; (...); Casanova Estruch, B.
Meeting Abstract. 2023
Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies
Navarro Canto, L.; (...); Casanova Estruch, B.
Meeting Abstract. 2019
Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype
Canto, LN; (...); Estruch, BC
Article. 10.3389/fneur.2019.01157. 2019
Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.
Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura
Article. 10.1002/brb3.2044. 2021
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions.
García-Lluch G; (...); Cháfer-Pericás C
Article. 10.14283/jpad.2024.16. 2024
Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
Quintanilla-Bordás C; (...); Casanova B
Article. 10.3389/fneur.2022.897275. 2022
Central nervous system manifestations in acute and chronic graft-versus-host disease.
Lambert N; (...); Maquet P
Article. 10.1093/brain/awae340. 2024
Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis
Gil-Perotin, S.; (...); Casanova, B.
Meeting Abstract. 2021
Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study
Lacruz-Ballester, L.; (...); Casanova-Estruch, B.
Meeting Abstract. 2021
Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms ( TRMN)
Calvete, Oriol; (...); Kanagal-Shamanna, Rashmi
Meeting Abstract. 10.1182/blood-2023-188701. 2023
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical Outcomes and Additional Treatment Course in a MS Cohort Treated with Cladribine
Oreja-Guevara, C.; (...); Gomez-Estevez, I.
Meeting Abstract. 2023
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-021-05165-7. 2021
Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Lopez-Soley, Elisabet; (...); Solana, Elisabeth
Meeting Abstract. 2022
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
Lopez-Soley E; (...); Solana E
Article. 10.3390/jpm12050743. 2022
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; (...); Casanova B
Article. 10.3389/fneur.2019.01008. 2019
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J; (...); López-Fando L
Article. 10.1002/nau.24276. 2020
Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Consensus on early detection of disease progression in patients with multiple sclerosis
Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia
Article. 10.3389/fneur.2022.931014. 2022
CRIDECO Anticholinergic Load Scale: An Updated Anticholinergic Burden Scale. Comparison with the ACB Scale in Spanish Individuals with Subjective Memory Complaints.
Ramos H; (...); Pardo J
Article. 10.3390/jpm12020207. 2022
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.
Brändle SM; (...); Dornmair K
Article. 10.1073/pnas.1916337118. 2021
CSF chitinase 3-like-1 association with disability of primary progressive MS
Perez-Miralles, F; (...); Casanova, B
Article. 10.1212/NXI.0000000000000815. 2020
Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis
Izquierdo Ayuso, G.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Chitinase 3-like 1 expression in the brain of different multiple sclerosis phenotypes
Gil-Perotin, S.; (...); Estruch, BC
Meeting Abstract. 2019
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Deciphering Multiple Sclerosis Progression.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos
Review. 10.3389/fneur.2021.608491. 2021
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura
Article. 10.1159/000519772. 2022
DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva, Luis; (...); Moral, Ester
Article. 10.1016/j.msard.2022.103805. 2022
Does benign multiple sclerosis exist?
Verdini Martinez, Laura; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1007/s13760-020-01516-x. 2020
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana, J E; (...); Calles Hernandez, C
Article. 10.1016/j.nrleng.2021.06.006. 2023
Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study
Meca-Lallana, J. E.; (...); Hernandez, C. Calles
Article. 10.1016/j.nrl.2021.06.007. 2024
Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
Oreja-Guevara, C.; (...); Meca-Lallana, J. E.
Meeting Abstract. 2021
Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz, David; (...); Casanova, Bonaventura
Article. 10.1007/s10072-023-06971-x. 2023
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE; (...); Llarena C
Article. 10.1007/s40120-023-00557-7. 2023
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcala, Carmen; (...); Casanova, Bonaventura
Article. 10.1007/s00415-022-10989-0. 2022
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Emotion recognition and baseline cortisol levels relationship in early Alzheimer Disease.
Ferrer-Cairols, I.; (...); Chafer-Pericas, C.
Article. 10.1016/j.biopsycho.2023.108511. 2023
Epilepsy, status epilepticus, and hemiplegic migraine coexisting with a novel SLC4A4 mutation.
Gil-Perotín S; (...); Díaz S
Article. 10.1007/s10072-020-04961-x. 2021
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco
Article. 10.3390/jpm12010119. 2022
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Evaluation of the retina and optic nerve after the use of stem cells for neurodegenerative disorders in an animal model
García-Gil R; (...); Gil-Perotin, S.
Article. 10.24875/RMO.M19000086. 2019
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba, Jessica; (...); Casanova, Bonaventura
Article. 10.3389/fimmu.2022.827738. 2022
Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.
Quesada-Simo, A.; (...); Gil-Perotin, S.
Article. 10.3389/fphar.2023.1186016. 2023
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
Meca-Lallana, Jose E.; (...); Maurino, Jorge
Article. 10.1007/s40120-022-00356-6. 2022
Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
Meca-Lallana, Jose; (...); Maurino, Jorge
Meeting Abstract. 10.1016/j.jns.2021.118844. 2021
Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study
Meca Lallana, Jose; (...); Forner, Mireia
Meeting Abstract. 10.1212/WNL.0000000000202381. 2023
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2023.104997. 2023
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Influence of Statin Potency and Liposolubility on Alzheimer's disease patients: a population-based study.
Garcia-Zamora, Mar; (...); Chafer-Pericas, Consuelo
Article. 10.1016/j.phrs.2024.107446. 2024
Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.
Baquero, Miguel; (...); Chafer-Pericas, Consuelo
Article. 10.3390/jcm13164735. 2024
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch
Article. 10.1016/j.msard.2023.105033. 2023
Leptomeningeal gadolinium enhancement in multiple sclerosis
Gascon-Gimenez, F; (...); Casanova, V
Meeting Abstract. 2019
Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience
Rubio Alcantud, Almudena; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Long-term experience with cladribine tablets in multiple sclerosis patients
Oreja-Guevara, Celia; (...); Alba Suarez, Elda Maria
Meeting Abstract. 2023
Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1016/j.jns.2020.117180. 2020
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
Garcia-Foncillas, J; (...); Gomez, MVP
Review. 10.1007/s40291-021-00544-4. 2021
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis
Article. 10.1212/NXI.0000000000200069. 2023
Neural organoids to model neuroinflammation: a systematic review focused on microglia's integration
Barea-Moya, L., Gil-Perotin, S., Garcia-Verdugo, J.
Meeting Abstract. 2023
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura
Article. 10.1007/s10072-023-07252-3. 2023
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I; (...); Villar LM
Article. 10.3389/fneur.2020.579438. 2020
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
Alcala, C.; (...); Casanova, B.
Article. 10.1007/s00415-021-10926-7. 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcala Vicente, Carmen; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2022.991596. 2022
Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity
Castillo, J.; (...); Casanova, B.
Meeting Abstract. 2022
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B; (...); Pérez-Miralles F
Article. 10.1016/j.msard.2022.104118. 2022
Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis.
Gil-Perotin, S.; (...); Solis-Tarazona, L.
Article. 10.1038/s41598-022-23088-x. 2022
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
Meca-Lallana, JE; (...); Maurino, J
Article. 10.2147/PPA.S305707. 2021
Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)
Lallana, Jose Meca; (...); Maurino, Jorge
Meeting Abstract. 2021
Potential Biomarkers Associated with Multiple Sclerosis Pathology.
Mathur, Deepali; (...); Casanova, Bonaventura
Article. 10.3390/ijms221910323. 2021
Potential Role of CHI3L1+ Astrocytes in Progression in MS.
Cubas-Núñez L; (...); Casanova B
Article. 10.1212/NXI.0000000000000972. 2021
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis.
Solis-Tarazona, Luis; (...); Gil-Perotin, Sara
Article. 10.3389/fneur.2024.1354431. 2024
Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Meca-Lallana, JE; (...); Ballesteros, J
Article. 10.1371/journal.pone.0255317. 2021
Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study
Meca-Lallana, J; (...); Maurino, J
Meeting Abstract. 2020
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Ramo-Tello, Cristina; (...); Rovira À
Article. 10.3390/jpm12010006. 2021
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reliability, validity and distribution of the Spanish female sexual function index in women with relapsing multiple sclerosis.
Gil-Perotin, Sara; (...); Sanchez-Sanchez, Beatriz
Article. 10.1186/s12905-023-02811-4. 2023
Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2022
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
Response to letter to the editor: An in-depth look at the relationship between anti-diabetic drugs and Alzheimer's disease.
Garcia-Zamora, Mar; (...); Pardo Albiach, Juan
Letter. 10.1016/j.phrs.2024.107396. 2024
Response to letter to the editor: Expanding perspectives on the relationship between statin potency and lipophilicity in Alzheimer's disease management.
Garcia-Zamora, Mar; (...); Pardo, Juan
Letter. 10.1016/j.phrs.2025.107595. 2025
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide, Georgina; (...); Meca-Lallana, Jose E
Article. 10.1212/NXI.0000000000001024. 2021
Selecting a Brief Cognitive Screening Test Based on Patient Profile: It Is Never Too Early to Start
Garcia-Lluch, Gemma; (...); Moreno, Lucrecia
Article. 10.3390/jcm13196009. 2024
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolas; (...); Comabella, Manuel
Article. 10.1136/jnnp-2023-332251. 2023
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2023
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis
Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
Pérez-Miralles F; (...); Casanova B
Article. 10.1016/j.msard.2021.102860. 2021
Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.
Balzano T; (...); Felipo V
Article. 10.1186/s12974-020-01746-z. 2020
Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective
Meca-Lallana, J.; (...); Maurino, J.
Meeting Abstract. 2021
Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2023.1060696. 2023
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete, Lamberto; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2021.727586. 2021
Use of individual measure and z-scores to monitor disease course in relapsing multiple sclerosis: a 1-year prospective study in a single center
Solis-Tarazona, L.; (...); Gil-Perotin, S.
Meeting Abstract. 2022
Use of individual measure and Z-scores to monitor disease course in Relapsing Multiple Sclerosis: A 1-year Prospective Study in a Single Center
Solis-Tarazona, Luis Rafael, Reddam, Salma, Gil-Perotin, Sara
Meeting Abstract. 10.1212/WNL.0000000000203193. 2023
Usefulness of susceptibility-weighted imaging in subacute cerebral fat embolism
Gil-Perotin, S, Carreres-Polo, J
Letter. 10.1016/j.nrleng.2019.01.005. 2019